--- title: 'Clinical Daily Summary: What Happened on October 19, 2026' headline: Gilead reports 23% placebo-adjusted remission rate for ulcerative colitis drug description: Other clinical updates include interim ovarian cancer survival data, smell-loss trial results and a small lung cancer combination study. url: https://thebench.bio/news/clinical/2026-10-19 topic: clinical date: '2026-10-19' covers: - '2026-10-19' date_published: '2026-10-19T12:01:46Z' date_modified: '2026-10-19T12:01:46Z' tags: - Clinical - Research sources: 4 publisher: TheBench.Bio --- # Clinical Daily Summary: What Happened on October 19, 2026 **Gilead reports 23% placebo-adjusted remission rate for ulcerative colitis drug** Other clinical updates include interim ovarian cancer survival data, smell-loss trial results and a small lung cancer combination study. ## Today in brief Emvistegrast achieved a 23% placebo-adjusted clinical remission rate after 12 weeks in Gilead’s Phase 2 study of moderate to severe ulcerative colitis. [1] Cyrano Therapeutics said CYR-064 met its Phase 2 safety endpoint, with efficacy signals among participants younger than 60. [2] In OSE Immunotherapeutics’ 106-person Phase 2 lung cancer trial, one-year survival was higher with both Tedopi combinations than with chemotherapy alone. [3] Zentalis reported interim median overall survival of 15.8 months for patients with Cyclin E1-positive ovarian cancer, versus 7.5 months for those without the marker. [4] ## Also worth knowing - In Zentalis’ DENALI Part 1b study, retrospective testing classified 48 patients as Cyclin E1-positive and 46 as negative. Investigators reported no newly identified safety signals in the interim review. [4] - Among FLAVOR trial participants younger than 60, high-dose CYR-064 improved two patient-reported smell measures more than placebo over 24 weeks. No serious adverse events were linked to treatment, and overall adverse-event rates were similar between groups. [2] - Gilead executive Swati Tole said the company sees potential for emvistegrast as an oral ulcerative colitis treatment. [1] - Combi-TED had no Tedopi-only group, so it could not determine how much benefit came from adding docetaxel or nivolumab. OSE expects results from its separate Phase 3 ARTEMIA trial in early 2028. [3] ## The day in numbers - **23%**: Placebo-adjusted remission rate with emvistegrast after 12 weeks in Phase 2 ulcerative colitis study [1] - **15.8 vs. 7.5 months**: Interim median overall survival for Cyclin E1-positive and Cyclin E1-negative groups, respectively, in DENALI Part 1b [4] - **151**: Participants enrolled in Cyrano’s Phase 2 FLAVOR trial of CYR-064 [2] - **106**: Participants in OSE’s Phase 2 Combi-TED trial [3] ## Also published - [Data reveal is promising for GSK's lung cancer drug ris-rez](), pharmaphorum - [Waiting to get sick enough](), Nature Medicine ## Sources 1. [STAT+: Gilead’s IBS drug eliminated symptoms for patients, mid-stage study finds](), STAT Biotech, 2026-10-19 2. [Cyrano’s Phase II trial of CYR-064 meets primary safety endpoint](), Clinical Trials Arena, 2026-10-19 3. [OSE reports positive Phase 2 data, but questions remain](), European Biotechnology, 2026-10-19 4. [Zentalis reports survival data from azenosertib ovarian cancer study](), Clinical Trials Arena, 2026-10-19 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: